title: Drug-induced rash with eosinophilia and systemic symptoms syndrome with bupropion administration.
abstract: BACKGROUND
  Sustained-release bupropion is commonly used for the symptomatic relief of depressive illness and as an adjuvant in smoking cessation therapy.
  
  
  OBJECTIVE
  To report a case of bupropion-induced drug rash with eosinophilia and systemic symptoms syndrome, including acute hepatitis, obstructive lung disease, and myositis.
  
  
  METHODS
  After the patient discontinued use of bupropion, serologic tests, muscle biopsies, pulmonary function tests, a chest x-ray examination, venous Doppler ultrasounds, and an electrocardiogram were performed.
  
  
  RESULTS
  On discontinuation of bupropion and prolonged systemic corticosteroid therapy, there was complete resolution of symptoms.
  
  
  CONCLUSIONS
  To our knowledge, this is the first reported case of drug rash with eosinophilia and systemic symptoms syndrome induced by bupropion therapy. We report this case to notify clinicians of the potential serious multisystem complications that can occur with sustained-release bupropion therapy.
authors.affiliation: Department of Medicine, Foothills Medical Centre, University of Calgary, Calgary, Alberta, Canada.
authors.forename: Sean M
authors.initials: SM
authors.lastname: Bagshaw
authors.forename: Bruce
authors.initials: B
authors.lastname: Cload
authors.forename: Janet
authors.initials: J
authors.lastname: Gilmour
authors.forename: Stephen T
authors.initials: ST
authors.lastname: Leung
authors.forename: Thomas J
authors.initials: TJ
authors.lastname: Bowen
mesh_terms: D000328:Adult; D018687:Antidepressive Agents, Second-Generation / Q000009:adverse effects*; D016642:Bupropion / Q000009:adverse effects*; D002170:Canada; D004802:Eosinophilia / Q000139:chemically induced* / Q000188:drug therapy / Q000276:immunology; D005076:Exanthema / Q000139:chemically induced* / Q000188:drug therapy / Q000276:immunology; D006505:Hepatitis / Q000188:drug therapy / Q000276:immunology; D006801:Humans; D008173:Lung Diseases, Obstructive / Q000139:chemically induced / Q000188:drug therapy / Q000276:immunology; D008297:Male; D009220:Myositis / Q000139:chemically induced / Q000188:drug therapy / Q000276:immunology; D010679:Philippines / Q000208:ethnology; D011239:Prednisolone / Q000627:therapeutic use; D016540:Smoking Cessation; D013577:Syndrome
chemical_list: D018687:Antidepressive Agents, Second-Generation; D016642:Bupropion; D011239:Prednisolone